New Jersey is confronting a staggering public health crisis brought about by prescription opioid abuse. On February 15, 2017, P.L. 2017, c. 28, was signed into law, imposing certain restrictions on how opioids and other Schedule II controlled dangerous substances may be prescribed. In response to the new law, the Attorney General and New Jersey's prescribing boards adopted new rules designed to reduce the risk of addiction and the accumulation of opioids in the household medicine cabinets across the State, which are very often diverted for illegal use. Information about those rules, as well as guidance for prescribers and patients on safer pain medication prescribing practices is available here.
- The generally applicable rules.
- The waivers of certain in-person examination requirements relating to the prescribing of CDS and the authorization of medical marijuana, allowing the use of telemedicine during the current public health emergency, as set forth in
Administrative Order 2020-15 (DCA AO-2020-15).
- The requirement to co-prescribe naloxone to chronic patients obtaining 90 MMEs or more of opioids or the concurrent prescription of an opioid and a benzodiazepine, as set forth in
Administrative Order 2020-08 (DCA AO-2020-08). (See FAQs)
|
Frequently Asked Questions
Agreements
Guidelines
What Patients Should Ask:
National Transportation Safety Board
The National Transportation Safety Board recommends that health care providers discuss with patients the effect their medical condition and medication may have on their ability to safely operate a vehicle in any mode of transportation.
Regulations
Please visit the appropriate prescribing Board website for full versions of the Board's regulations.
Please read below for the Prescribing Limitations and Management of Acute and Chronic Pain rule language adopted by each prescribing Board on May 1, 2017.
Statutes